Orthoscan

Orthoscan

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14M

Overview

Orthoscan is a private, commercial-stage medical device company focused on the mobile C-arm imaging market, primarily for orthopedics. The company has a portfolio of products, including the TAU series and Versa systems, which emphasize reduced radiation dose, portability, and flat-panel technology. It operates a full business model encompassing manufacturing, sales, service, and financing, targeting surgical centers, clinics, and hospitals. Orthoscan's strategy is built on direct customer relationships, nationwide service support, and a focus on innovative imaging solutions for procedural guidance.

OrthopedicsSurgery

Technology Platform

Mobile C-arm fluoroscopic imaging systems with focus on mini C-arms, flat-panel digital detectors, and dose optimization technology for surgical and clinical guidance.

Funding History

2
Total raised:$14M
Series A$12M
Seed$2M

Opportunities

Growth is driven by the expansion of ambulatory surgical centers and the shift to outpatient orthopedic procedures, which increase demand for compact, point-of-care imaging.
The ongoing industry-wide transition from older image intensifiers to modern digital flat-panel detectors creates a sustained upgrade cycle for existing customers.

Risk Factors

The company faces intense competition from large, well-resourced medical imaging conglomerates and other specialized firms.
It is also exposed to cyclical hospital capital expenditure budgets and potential pressure from changing healthcare reimbursement policies for surgical procedures.

Competitive Landscape

Orthoscan competes in a crowded market dominated by global giants like Siemens, GE, and Philips, as well as other focused players like Ziehm Imaging, Hologic, and Shimadzu. Its strategy is to compete on specialization in orthopedic imaging, dose reduction, portability, and customer service rather than attempting to match the full portfolio of the largest competitors.